Go Pro
NASDAQ:PGNY

Progyny Q2 2026 Earnings Report

Progyny logo
$31.49 -0.04 (-0.12%)
As of 12:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Progyny EPS Results

Actual EPS
N/A
Consensus EPS
$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

Progyny Revenue Results

Actual Revenue
N/A
Expected Revenue
$348.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Progyny Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
4:45PM ET

Conference Call Resources

Progyny Earnings Headlines

Progyny's (PGNY) Equal Weight Rating Reiterated at Barclays
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas conflict - could be the worst thing to hit American investors in 50 years, potentially keeping portfolios in the red for a decade or more. TradeSmith CEO Keith Kaplan is responding with an AI-driven trading tool built by a former U.S. Air Force nuclear missile coder, designed to sidestep sudden market crashes while still growing your money - regardless of whether markets rise, fall, or stay flat. No options, gold, crypto, or penny stocks involved.tc pixel
Progyny (NASDAQ:PGNY) Stock Rating Lowered by Wall Street Zen
See More Progyny Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Progyny? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Progyny and other key companies, straight to your email.

About Progyny

Progyny (NASDAQ:PGNY) is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package. Through an in-house network of fertility specialists and clinics, Progyny provides members with access to pre-negotiated pricing, personalized treatment pathways and dedicated care advocates. Complementing these services is a suite of digital resources, including appointment scheduling tools, educational content and real-time treatment tracking, designed to simplify care coordination and reduce administrative burdens.

Founded in 2016, Progyny filed for its initial public offering in October 2019 and began trading on the NASDAQ under the ticker PGNY. The company was established by Michael J. Schulman, who serves as chief executive officer and has guided its growth from a startup to a publicly traded business. Under his leadership, Progyny has expanded its team of clinical advisors and invested in technology to enhance patient engagement and clinical decision support.

Progyny’s services are currently available throughout the United States, with corporate clients spanning technology, finance, manufacturing and other sectors. Headquartered in New York City, the company maintains additional offices in major U.S. markets and collaborates with employers nationwide to provide scalable, outcomes-driven fertility solutions. By combining clinical best practices with data-driven insights, Progyny seeks to set new standards in reproductive healthcare benefits.

View Progyny Profile